Cargando…

CCR9 Antagonists in the Treatment of Ulcerative Colitis

While it has long been established that the chemokine receptor CCR9 and its ligand CCL25 are essential for the movement of leukocytes into the small intestine and the development of small-intestinal inflammation, the role of this chemokine-receptor pair in colonic inflammation is not clear. Toward t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bekker, Pirow, Ebsworth, Karen, Walters, Matthew J., Berahovich, Robert D., Ertl, Linda S., Charvat, Trevor T., Punna, Sreenivas, Powers, Jay P., Campbell, James J., Sullivan, Timothy J., Jaen, Juan C., Schall, Thomas J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592714/ https://www.ncbi.nlm.nih.gov/pubmed/26457007 http://dx.doi.org/10.1155/2015/628340

Ejemplares similares

A Systemically-Administered Small Molecule Antagonist of CCR9 Acts as a Tissue-Selective Inhibitor of Lymphocyte Trafficking
por: Tubo, Noah J., et al.
Publicado: (2012)

CCR2 antagonism leads to marked reduction in proteinuria and glomerular injury in murine models of focal segmental glomerulosclerosis (FSGS)
por: Miao, Zhenhua, et al.
Publicado: (2018)

Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study
por: Bekker, Pirow, et al.
Publicado: (2016)

Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study
por: Bekker, Pirow, et al.
Publicado: (2019)

The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells
por: Zabel, Brian A, et al.
Publicado: (2011)

Combination therapy of chemokine receptor inhibition plus PDL-1 blockade potentiates anti-tumor effects in a murine model of breast cancer
por: Jung, Heiyoun, et al.
Publicado: (2015)

A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s Disease
por: Keshav, Satish, et al.
Publicado: (2013)

Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats
por: Walters, M J, et al.
Publicado: (2014)

Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis
por: Lukin, Dana, et al.
Publicado: (2020)

Biologics in the management of ulcerative colitis – comparative safety and efficacy of TNF-α antagonists
por: Fausel, Rebecca, et al.
Publicado: (2015)

The Increased Expression of CCL20 and CCR6 in Rectal Mucosa Correlated to Severe Inflammation in Pediatric Ulcerative Colitis
por: Uchida, Keiichi, et al.
Publicado: (2015)

Ulcerative Colitis of Psychogenic Origin: A Report of Six Cases
por: Sullivan, Albert J., et al.
Publicado: (1932)

In silco analysis of carboxamide derivatives of piperidine as potential antagonists of CCR5
por: Harishchander, A, et al.
Publicado: (2014)

Modulation of inflammatory pain in response to a CCR2/CCR5 antagonist in rodent model
por: Okamoto, Masayuki, et al.
Publicado: (2013)

What is the future of CCR5 antagonists in rheumatoid arthritis?
por: Takeuchi, Tsutomu, et al.
Publicado: (2012)

Short-term variation of HIV tropism readouts in the absence of CCR5 antagonists
por: Brumme, CJ, et al.
Publicado: (2010)

Eosinophilic Gastroenteritis in an Ulcerative Colitis Patient During Treatment with Tumor Necrosis Factor-alpha Antagonist
por: Hayashida, Sho, et al.
Publicado: (2020)

ULCERATIVE COLITIS
Publicado: (1969)

Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: Merkel, Peter A., et al.
Publicado: (2020)

CCR5 and CXCR4 antagonist and agonist binding sites
por: Teintze, Martin, et al.
Publicado: (2006)

Evolution of coreceptor utilization to escape CCR5 antagonist therapy
por: Zhang, Jie, et al.
Publicado: (2016)

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
por: Lefebvre, Eric, et al.
Publicado: (2016)

Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment
por: Lefebvre, E, et al.
Publicado: (2016)

High prevalence of ulcerative appendicitis in patients with ulcerative colitis
por: Heuthorst, Lianne, et al.
Publicado: (2021)

Ulcerative Colitis-Symptom Questionnaire: Valid for Use in Adults with Moderately to Severely Active Ulcerative Colitis
por: Panes, Julian, et al.
Publicado: (2023)

Potent CCR3 Receptor Antagonist, SB328437, Suppresses Colonic Eosinophil Chemotaxis and Inflammation in the Winnie Murine Model of Spontaneous Chronic Colitis
por: Filippone, Rhiannon T., et al.
Publicado: (2022)

New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists
por: Schlecht, Hans P, et al.
Publicado: (2008)

Autoimmune Enteropathy in an Ulcerative Colitis Patient
por: Rodriguez, Nicolette J., et al.
Publicado: (2018)

CCR3 antagonist impairs estradiol-induced eosinophil migration to the uterus in ovariectomized mice
por: Araújo, J.M.D., et al.
Publicado: (2019)

Production of Corn Protein Hydrolysate with Glutamine-Rich Peptides and Its Antagonistic Function in Ulcerative Colitis In Vivo
por: Jing, Yan, et al.
Publicado: (2022)

Hemophilia A Complicated by Ulcerative Colitis
por: Olivier, Maxim, et al.
Publicado: (2018)

Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme
por: Winthrop, Kevin L, et al.
Publicado: (2020)

Epigenetic Signatures Discriminate Patients With Primary Sclerosing Cholangitis and Ulcerative Colitis From Patients With Ulcerative Colitis
por: de Krijger, Manon, et al.
Publicado: (2022)

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis
por: Puengel, Tobias, et al.
Publicado: (2022)

Maraviroc – A CCR5 Antagonist for the Treatment of HIV-1 Infection
por: Van Der Ryst, Elna
Publicado: (2015)

Screening of chemokine receptor CCR4 antagonists by capillary zone electrophoresis
por: Sun, Zhe, et al.
Publicado: (2011)

Infliximab in ulcerative colitis
por: Levin, Avi, et al.
Publicado: (2008)

Ulcerative Colitis in Infancy
por: Rukunuzzaman, Md, et al.
Publicado: (2011)

Management of ulcerative colitis
por: Fell, John M, et al.
Publicado: (2016)

Chronic Ulcerative Colitis
por: Sen, S. C.
Publicado: (1939)

Cannot write session to /tmp/vufind_sessions/sess_h100d2bjf3ellstqb1iuo517h2